Loring Wolcott & Coolidge Fiduciary Advisors LLP MA Increases Stake in Becton, Dickinson and Company (NYSE:BDX)

Loring Wolcott & Coolidge Fiduciary Advisors LLP MA lifted its stake in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 135.2% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 22,936 shares of the medical instruments supplier's stock after acquiring an additional 13,186 shares during the quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA's holdings in Becton, Dickinson and Company were worth $5,473,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in BDX. Livelsberger Financial Advisory bought a new position in shares of Becton, Dickinson and Company in the third quarter worth about $26,000. Sound Income Strategies LLC raised its position in shares of Becton, Dickinson and Company by 35.8% during the third quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier's stock valued at $40,000 after buying an additional 44 shares during the last quarter. Opal Wealth Advisors LLC purchased a new position in shares of Becton, Dickinson and Company in the second quarter worth $45,000. Abound Wealth Management grew its stake in Becton, Dickinson and Company by 96.0% during the second quarter. Abound Wealth Management now owns 196 shares of the medical instruments supplier's stock valued at $46,000 after acquiring an additional 96 shares in the last quarter. Finally, Chilton Capital Management LLC lifted its stake in Becton, Dickinson and Company by 1,233.3% in the 2nd quarter. Chilton Capital Management LLC now owns 200 shares of the medical instruments supplier's stock worth $47,000 after purchasing an additional 185 shares in the last quarter. 86.97% of the stock is owned by hedge funds and other institutional investors.

Becton, Dickinson and Company Trading Down 0.4 %

Shares of NYSE BDX traded down $0.94 during midday trading on Wednesday, hitting $236.57. The company's stock had a trading volume of 562,510 shares, compared to its average volume of 1,370,584. The business's 50 day moving average is $237.58 and its two-hundred day moving average is $235.04. Becton, Dickinson and Company has a 12-month low of $218.75 and a 12-month high of $259.92. The company has a current ratio of 1.85, a quick ratio of 1.36 and a debt-to-equity ratio of 0.70. The firm has a market cap of $68.37 billion, a P/E ratio of 52.31, a price-to-earnings-growth ratio of 1.79 and a beta of 0.42.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last released its earnings results on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share for the quarter, topping the consensus estimate of $3.31 by $0.19. The business had revenue of $4.99 billion during the quarter, compared to the consensus estimate of $5.08 billion. Becton, Dickinson and Company had a return on equity of 14.49% and a net margin of 7.13%. The business's revenue for the quarter was up 2.3% compared to the same quarter last year. During the same period last year, the company earned $2.96 earnings per share. As a group, equities research analysts expect that Becton, Dickinson and Company will post 13.11 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the company. Stifel Nicolaus lifted their target price on Becton, Dickinson and Company from $270.00 to $280.00 and gave the stock a "buy" rating in a report on Friday, July 26th. Evercore ISI upped their price target on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the company an "outperform" rating in a research note on Tuesday, October 1st. StockNews.com raised shares of Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a research note on Thursday, August 8th. Citigroup upgraded Becton, Dickinson and Company from a "neutral" rating to a "buy" rating and lifted their price target for the stock from $255.00 to $275.00 in a research report on Tuesday, October 1st. Finally, Raymond James decreased their price objective on Becton, Dickinson and Company from $275.00 to $270.00 and set an "outperform" rating on the stock in a research report on Friday, August 2nd. Nine equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $282.63.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.